Defibrotide Dose-escalation for SOS Post-HSCT

This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.

NCT Number	NCT05987124
Lead Sponsor	New York Medical College
Conditions	Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
Enrollment	20 participants
Start Date	2024-03-20
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-15